![Meloxicam (Amelotex) gel 1% - [50 g tube]](https://mediscom.com.co/wp-content/uploads/2022/11/Amelotex-1pct-30g.webp)
Description
Amelotex Pharmacodynamics
AMELOTEX® gel contains meloxicam – a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory effect. Anti-inflammatory effect is associated with inhibition of enzymatic activity of cyclooxygenase-2 (COX-2), involved in the biosynthesis of prostaglandins in the area of inflammation. To a lesser extent, meloxicam acts on cyclooxygenase-1 (COX-1), involved in the synthesis of prostaglandin, which protects the mucosa of the gastrointestinal tract and is involved in the regulation of blood flow in the kidneys. Meloxicam is a “chondroneutral” drug, has no adverse effect on cartilage tissue, does not affect the synthesis of proteoglycan by chondrocytes of articular cartilage. When applied topically, the drug reduces
or eliminates pain in the area of application of the gel, including joint pain at rest and during movement. Helps to increase the volume of movement.
Indications
Symptomatic treatment of osteoarthritis, accompanied by pain syndrome. Post-traumatic pain syndrome (traumatic contusions, dislocations, injuries of ligaments, muscles and tendons, muscle tears without compromising the integrity of the skin).
Used for symptomatic therapy, reduction of pain and inflammation; does not affect the progression of the disease.
Contraindications
Hypersensitivity to meloxicam and other components of the drug (including other NSAIDs);
Complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and sinuses and intolerance to acetylsalicylic acid or other NSAIDs (including anamnesis), violation of the integrity of the skin in the area of intended application;
Children (under 18 years of age) (effectiveness and safety has not been established);
Pregnancy and breast-feeding.
With caution: gastric and 12 duodenal ulcer (acute phase), active gastrointestinal bleeding; advanced renal disease, severe hepatic insufficiency or active liver disease, confirmed hyperkalemia, inflammatory bowel disease, advanced age, clotting disorders, chronic heart failure.
Administration during pregnancy and lactation
The drug is contraindicated during pregnancy and breast-feeding.
Dosage and administration method.
- Outwardly. Do not use internally!
- A 4 cm long strip of gel (2 g) is applied 2 times a day, a thin layer on clean, dry skin over the lesion and gently rub for 2-3 minutes. Duration of therapy course is determined individually, may vary depending on the lesion and the observed therapeutic effect, and is no more than 4 weeks.
